Answers are grounded in this paper and cite their sources.
To meet the clinical demand emerging with the changing paradigm in both diagnosis and treatment, the medical imaging techniques also proceeds into precision stage, becomes the major tasks beyond screening, early detection, staging and therapy evaluation. As heterogeneity of malignant tumors have major impacts on both scientific and clinical interests in CRC, multiple features are needed to be uncovered in order to better stratify and select the subgroups in view of their response status to the treatment and other biological characters. Multi-modality imaging, like PET/CT and PET/MR, using multi-biomarker specifically binding to key-targets in tumor and in microenvironment, might be the best choice for the goal.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: